Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy

Trial Profile

Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2015

At a glance

  • Drugs Enobosarm (Primary)
  • Indications Cachexia
  • Focus Registrational; Therapeutic Use
  • Acronyms POWER2
  • Sponsors GTx
  • Most Recent Events

    • 18 Dec 2013 New trial record
    • 13 Nov 2013 Planned End Date changed from 1 Aug 2013 to 1 Apr 2014, according to ClinicalTrials.gov.
    • 24 Oct 2013 Results will be presented at the 15th World Conference on Lung Cancer, according to a GTx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top